Technology

Safety issues of currently used steroids

Currently-used steroids carry a class warning and are not approved to be administered epidurally for the treatment of sciatica. In fact, there are further warnings that the safety and efficacy of the use of these products following epidural administration has not been established.

Their formulations include neurotoxic preservatives, surfactants, suspensions or particulates that carry risks of serious neurologic complications.

Unlike currently-used steroids, SP-102 does not contain neurotoxic preservatives, surfactants, suspensions or particulates that carry risk of serious neurologic complications, which we believe may improve safety and the extent of pain relief. By using dexamethasone sodium phosphate, the soluble form of the potent dexamethasone, we believe SP-102 may substantially reduce the risk of embolic events in case of inadvertent intra-arterial administration and enable repeat injections.

We expect the injectable viscous gel product, SP-102, which uses a biocompatible, biodegradable, novel excipient and is protected by multiple patents and patent applications and trade secrets, to prolong the residence time at the injection site and result in extended local activity. We believe SP-102, if successfully developed and approved, has the potential to reduce the disability related to lumbosacral radicular pain and help delay or avoid spine surgery.

Our Solution

We are developing SP-102 to address problems associated with currently available corticosteroid products that are used in practice but not approved for epidural injection or the treatment of lumbosacral radicular pain (LRP) also called “sciatica”. SP-102 is a Phase 3 sterile dexamethasone sodium phosphate viscous gel formulation of 10 mg dexamethasone at a 5 mg/mL concentration in a pre-filled glass syringe for delivery via an epidural injection.

SP-102 allows for the use of the potent dexamethasone and provides for longer residency time at the site of injection through the use of a viscous excipient in lieu of particulates. The product is also formulated without the use of preservatives and packaged in a pre-filled syringe, so as to confer greater physician convenience.

SP-102 (SEMDEXA™) Technology Highlights
  • SP-102 is a preservative free, surfactant free and particulate free viscous gel formulation of dexamethasone for sciatica (lumbosacral radicular pain).
  • Extended local effect provides durable pain relief and significant improvement in functioning from a single injection with rapid onset.
  • Improvement against placebo over 4 weeks and continued effect over 12 weeks with reduced use of rescue therapy.
  • Good safety profile for single and repeat injections.
  • Common epidural delivery by minimally invasive procedure conducted in outpatient pain clinics.
  • Stable at refrigerated temperature in a prefilled syringe.
Lumbosacral Radicular Pain (Sciatica)
  • Lifetime incidence 13 – 40%
  • Rarely diagnosed before the age of 20, peaks in the 50s and declines thereafter
  • ~ 90% of cases caused by a herniated disc with nerve root compression
Clinical features of herniated lumbar nucleus pulposus
Epidural Injection Time Course: Post-injection